bexarotene has been researched along with Acute Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreadis, C; Bagg, A; Carroll, M; DiPatri, D; Ghalie, R; Goldsteini, S; Goradia, A; Kemner, A; Loren, AW; Luger, SM; Nowell, P; Perl, A; Porter, D; Schuster, S; Stadtmauer, EA; Swider, C; Thompson, JE; Tomczak, E; Tsai, DE | 1 |
| Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W | 1 |
2 other study(ies) available for bexarotene and Acute Disease
| Article | Year |
|---|---|
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bexarotene; Bone Marrow; Cell Differentiation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloid Cells; Retinoid X Receptors; Tetrahydronaphthalenes | 2007 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2008 |